Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 3,685 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-Small Cell Lung Clear all
Completed Phase 3 Interventional Results available

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

NCT01351415
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Bevacizumab, Docetaxel, Erlotinib, Pemetrexed
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
68
States / cities
Mobile, Alabama • Glendale, Arizona • Jonesboro, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 28, 2026, 8:43 PM EDT
Terminated Phase 2 Interventional Results available

GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line

NCT01049776
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pazopanib (GW786034)
Drug
Lead sponsor
Illinois CancerCare, P.C.
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
13
States / cities
Bloomington, Illinois • Canton, Illinois • Carthage, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 28, 2026, 8:43 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT04743505
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
APL-101, Osimertinib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

NCT00356122
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Docetaxel, Oxaliplatin, Bevacizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Phase 1 Interventional

A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors

NCT02955251
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-428, Nivolumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Scottsdale, Arizona • Sacramento, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 28, 2026, 8:43 PM EDT
Completed No phase listed Observational

EBUS TBNA After PET/CT in Diagnosing Patients With Stage I-IIA Non-small Cell Lung Cancer Evaluated for Stereotactic Body Radiation Therapy

NCT02719847
View directory record Official record
Conditions
Lung Cancer
Interventions
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 28, 2026, 8:43 PM EDT
Enrolling by invitation No phase listed Observational

Development and Analysis of a Stool Bank for Cancer Patients

NCT04291755
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal
Interventions
Pembrolizumab Injection
Drug
Lead sponsor
Persephone Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Fountain Valley, California • Winter Haven, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 28, 2026, 8:43 PM EDT
Recruiting Phase 1 Interventional

A Study of VET3-TGI in Patients With Solid Tumors

NCT06444815
View directory record Official record
Conditions
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Urothelial Carcinoma Bladder, Squamous Cell Carcinoma
Interventions
VET3-TGI, Atezolizumab
Drug
Lead sponsor
KaliVir Immunotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Not applicable Interventional Results available

A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil

NCT01317550
View directory record Official record
Conditions
Lung Cancer
Interventions
Armodafinil, Placebo, Minocycline, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 28, 2026, 8:43 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

NCT04267848
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Observation Activity, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Questionnaire Administration
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1150
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 747 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

NCT01478685
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Tumor Virus Infections
Interventions
CC-486, Carboplatin, ABI-007
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Phase 1 Interventional

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

NCT01859026
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
MEK162, Erlotinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 28, 2026, 8:43 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

NCT07160335
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
Interventions
HLX17, US-sourced Keytruda®
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years to 85 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Glendale, California • Los Alamitos, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 8:43 PM EDT
Recruiting Phase 2 Interventional

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478
View directory record Official record
Conditions
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer
Interventions
HER3-DXd
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Duarte, California • New Haven, Connecticut • Kissimmee, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Phase 2 Interventional Results available

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

NCT02759835
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Neoplasms
Interventions
osimertinib, Local Ablative Therapy (LAT)
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 28, 2026, 8:43 PM EDT
Terminated Phase 1 Interventional

Immunization of Patients With Non Small Cell Lung Cancer (NSCLC)

NCT00793208
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
semi-allogeneic human fibroblasts (MRC-5) transfected with DNA
Biological
Lead sponsor
Theresa Whiteside, PhD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Phase 1 Interventional

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

NCT00622674
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cetuximab, bortezomib
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 28, 2026, 8:43 PM EDT
Terminated Phase 2 Interventional

Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases

NCT00121420
View directory record Official record
Conditions
Neoplasm Metastasis, Brain Neoplasms
Interventions
Motexafin gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Cleveland, Ohio + 6 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 28, 2026, 8:43 PM EDT
Terminated Phase 1 Interventional

Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer

NCT01187615
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed, Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
New Haven, Connecticut • Las Vegas, Nevada • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 28, 2026, 8:43 PM EDT
Terminated Phase 2 Interventional Results available

Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)

NCT01029925
View directory record Official record
Conditions
Metastatic Breast Cancer, Lung Cancer
Interventions
Dichloroacetate (DCA)
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 28, 2026, 8:43 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

NCT02638090
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
Vorinostat, Pembrolizumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Phase 2 Interventional

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

NCT00622193
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
anamorelin HCl, placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Little Rock, Arkansas • Melbourne, Florida • Augusta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Phase 2 Interventional Results available

Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer

NCT00247416
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
Gemcitabine, Dexamethasone, Carboplatin
Drug
Lead sponsor
Susanne Arnold
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
7
States / cities
Danville, Kentucky • Lexington, Kentucky • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 28, 2026, 8:43 PM EDT
Completed Not applicable Interventional

Computer-Assisted Scheduling of Nicotine Inhaler Use in Participants Who Plan to Stop Smoking

NCT00021138
View directory record Official record
Conditions
Esophageal Cancer, Head and Neck Cancer, Lung Cancer
Interventions
smoking cessation intervention, nicotine
Behavioral · Drug
Lead sponsor
Personal Improvement Computer Systems
Other
Eligibility
18 Years to 67 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Reston, Virginia
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 28, 2026, 8:43 PM EDT